Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax

Total 13 results found. Search for [ Biocon's performance ]

Results 1 to 13 of 13
PB Jayakumar
New Delhi, October 29, 2018
A big transformation is happening in the global generic pharmaceutical industry. As a result, stocks of most major drug companies have done badly in the past one year.

E Kumar Sharma
New Delhi, October 25, 2018
Kiran Mazumdar-Shaw said Biocon delivered a strong revenue growth of 35 per cent this quarter, driven by robust performance across our biologics, small molecules and research services segments.

E Kumar Sharma
New Delhi, April 27, 2018
While Biocon's Q4 results show margins below expectations, the market is more focused on the company's progress on the biosimilar front.

BT Online
April 28, 2017
Sensex drops 111.34 points to end at 29,918.40; Nifty falls 38.10 points to 9,304.05.

New Delhi, January 22, 2016
Standalone total income from operations of the company also rose to Rs 280.4 crore for the quarter under consideration as against Rs 227.6 crore for the same period year ago.

New Delhi, October 21, 2015
The consolidated revenue of Biocon was up by 11.38 per cent at Rs 861 crore during the quarter compared to Rs 773 crore in the year-ago period.

Alokesh Bhattacharyya and Sarika Malhotra
September 11, 2015
Business Today's 12th annual listing of women achievers. We drew up a long list of over 150 women and then shortlisted 55 contenders. Finally, 25 made the cut after jury deliberations.

E. Kumar Sharma
April 30, 2015
On the branded formulations business where the company is rationalising its presence to focus on some key areas, Kiran Mazumdar-Shaw, Chairperson and MD, Biocon said even this was expected to contribute $200 million dollars in the billion-dollar pie by 2018-19.

Shweta Punj, Anilesh S. Mahajan Venkatesha Babu and Nevin John
February 12, 2015
A million Indians join the workforce every month. What can Arun Jaitley's Budget and Narendra Modi's Make in India do for them?

New Delhi, January 23, 2014
The growth for this quarter has been led by the company's flagship drug brands - Basalog, Insupen, BioMab EGFR and Abraxane.

BT Online Bureau
New Delhi, July 26, 2013
Biocon has reported a 18.65 per cent rise in consolidated net profit at Rs 93.50 for the first quarter ended June 30, mainly on account of strong performance in the biopharma segment.

New Delhi, October 22, 2010
Biotechnology major Biocon on Friday reported 20.26 per cent increase in net profit for the quarter ended September 30 to Rs 89.22 crore on the back of strong sales in the biopharmaceuticals segment.

Team BT
October 2, 2008
They span generations and are there in every field, from biscuits to banking, from HR to hospitals. Denied entry into a male bastion, they create another industry. They are the most powerful women in the corporate world.